Icu Medical earnings release, August 6, 2026
ICU Medical Announces Second Quarter 2026 Results and Updates its Fiscal Year 2026 Guidance
SAN CLEMENTE, Calif., August 6, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended June 30, 2026.
Second Quarter 2026 Results
The following year-over-year results reflect the strategic divestiture of the IV Solutions business on May 1, 2025. Second quarter 2026 GAAP revenue increased 1% year-over-year; however, excluding the impact of the IV Solutions divestiture and foreign currency, non-GAAP organic revenue increased 6%.
Second quarter 2026 GAAP revenue was $551.7 million, as compared to $548.9 million in the same period in the prior year. GAAP gross profit for the second quarter of 2026 was $235.1 million, as compared to $208.1 million in the same period in the prior year. GAAP gross margin for the second quarter of 2026 was 43%, as compared to 38% in the same period in the prior year. GAAP net income for the second quarter of 2026 was $19.1 million, or $0.76 per diluted share, as compared to GAAP net income of $35.3 million, or $1.43 per diluted share, for the second quarter of 2025. Adjusted diluted earnings per share for the second quarter of 2026 was $2.37 as compared to $2.10 for the second quarter of 2025. Adjusted EBITDA was $110.0 million for the second quarter of 2026 as compared to $100.3 million for the second quarter of 2025.
Adjusted EBITDA and adjusted diluted earnings per share are measures calculated and presented on the basis of methodologies other than in accordance with GAAP. Please refer to the Use of Non-GAAP Financial Information following the financial statements herein for further discussion and reconciliations of these measures to GAAP measures.
Vivek Jain, ICU Medical’s Chief Executive Officer, said, “Second quarter results were ahead of our expectations for Infusion Systems and generally in line with expectations for the remainder of the business."
Revenues by product line for the three and six months ended June 30, 2026 and 2025 were as follows (in millions):
*On May 1, 2025, we disposed of our IV Solutions business which was included within our Vital Care product line. Vital Care includes contract manufacturing revenue of $3.8 million and $8.2 million for the three and six months ended June 30, 2026, respectively, as compared to $5.3 million and $10.5 million for the three and six months ended June 30, 2025, respectively.
** Totals may differ from the income statement due to the rounding of product lines.
Fiscal Year 2026 Guidance
For Fiscal Year 2026 the Company is updating its estimates of GAAP net income from a range of $26 million to $44 million to a range of $73 million to $83 million and GAAP diluted earnings per share from a range of $1.03 to $1.74 to a range of $2.89 to $3.29. The Company is updating the estimate of its full year 2026 guidance of Adjusted EBITDA from a range of $400 million to $430 million to a range of $415 million to $435 million and diluted earnings per share from a range of $7.75 to $8.45 to a range of $8.60 to $9.00.
Conference Call
The Company will host a conference call to discuss its second quarter financial results, today at 4:30 p.m. ET (1:30 p.m. PT). The call can be accessed at (800) 420-1459, conference ID "ICUMED". The conference call will be simultaneously available by webcast, which can be accessed by going to the Company's website at www.icumed.com, clicking on the Investors tab, clicking on Event Calendar and clicking on the Webcast icon and following the prompts. The webcast will also be available by replay.
About ICU Medical
ICU Medical (Nasdaq: ICUI) is a global leader in infusion systems, infusion consumables and high-value critical care products used in hospital, alternate site and home care settings. Our team is focused on providing quality, innovation and value to our clinical customers worldwide. ICU Medical is headquartered in San Clemente, California. More information about ICU Medical can be found at www.icumed.com.
Financial statements
Income Statement
Three months ended June 30, — (In thousands, except per share data)
| Three months ended June 30, – 2026 | Three months ended June 30, – 2025 | Six months ended June 30, – 2026 | Six months ended June 30, – 2025 | ||
|---|---|---|---|---|---|
| TOTAL REVENUES | 551,683 | 548,866 | 1,081,908 | 1,153,568 | |
| COST OF GOODS SOLD | 316,630 | 340,802 | 640,629 | 735,395 | |
| GROSS PROFIT | 235,053 | 208,064 | 441,279 | 418,173 | |
| OPERATING EXPENSES: | Selling, general and administrative | 151,922 | 159,392 | 306,488 | 316,625 |
| OPERATING EXPENSES: | Research and development | 22,702 | 21,867 | 43,982 | 45,158 |
| OPERATING EXPENSES: | Restructuring, strategic transaction and integration | 21,302 | 16,218 | 38,103 | 32,915 |
| OPERATING EXPENSES: | TOTAL OPERATING EXPENSES | 195,926 | 197,477 | 388,573 | 394,698 |
| OPERATING EXPENSES: | INCOME FROM OPERATIONS | 39,127 | 10,587 | 52,706 | 23,475 |
| OPERATING EXPENSES: | INTEREST EXPENSE, net | -15,747 | -20,549 | -32,241 | -42,580 |
| OPERATING EXPENSES: | OTHER (EXPENSE) INCOME, net | -236 | 1,818 | -1,296 | 55 |
| OPERATING EXPENSES: | GAIN ON SALE OF BUSINESS | 41,823 | 41,823 | ||
| OPERATING EXPENSES: | INCOME BEFORE INCOME TAXES AND EQUITY IN EARNINGS OF UNCONSOLIDATED AFFILIATES | 23,144 | 33,679 | 19,169 | 22,773 |
| OPERATING EXPENSES: | (PROVISION) BENEFIT FOR INCOME TAXES | -7,070 | -1,178 | 27,644 | -5,748 |
| OPERATING EXPENSES: | NET INCOME FROM CONSOLIDATED COMPANIES | 16,074 | 32,501 | 46,813 | 17,025 |
| OPERATING EXPENSES: | EQUITY IN EARNINGS OF UNCONSOLIDATED AFFILIATES | 3,013 | 2,837 | 2,406 | 2,837 |
| OPERATING EXPENSES: | NET INCOME | 19,087 | 35,338 | 49,219 | 19,862 |
| NET INCOME PER SHARE | Basic | 0.76 | 1.43 | 1.98 | 0.81 |
| NET INCOME PER SHARE | Diluted | 0.76 | 1.43 | 1.96 | 0.8 |
| WEIGHTED AVERAGE NUMBER OF SHARES | Basic | 25,000 | 24,645 | 24,884 | 24,593 |
| WEIGHTED AVERAGE NUMBER OF SHARES | Diluted | 25,044 | 24,708 | 25,132 | 24,746 |
Income Statement
(In thousands) (in thousands)
| Adjusted EBITDA – Three months ended June 30, – 2026 | Adjusted EBITDA – Three months ended June 30, – 2025 | ||
|---|---|---|---|
| GAAP net income | 19,087 | 35,338 | |
| Non-GAAP adjustments: | Interest, net | 15,747 | 20,549 |
| Non-GAAP adjustments: | Stock compensation expense | 11,870 | 14,457 |
| Non-GAAP adjustments: | Depreciation and amortization expense | 49,614 | 49,665 |
| Non-GAAP adjustments: | Restructuring, strategic transaction and integration | 21,302 | 16,218 |
| Non-GAAP adjustments: | Settlements | 30 | 150 |
| Non-GAAP adjustments: | Quality system and product-related remediation | 5,890 | 5,706 |
| Non-GAAP adjustments: | Gain on sale of business | -41,823 | |
| Non-GAAP adjustments: | Noncash release of loss on contract provision | -1,120 | -717 |
| Non-GAAP adjustments: | Gross profit on contract manufacturing | -575 | -412 |
| Non-GAAP adjustments: | Tariff refunds | -18,888 | |
| Non-GAAP adjustments: | Provision for income taxes | 7,070 | 1,178 |
| Non-GAAP adjustments: | Total non-GAAP adjustments | 90,940 | 64,971 |
| Non-GAAP adjustments: | Adjusted EBITDA | 110,027 | 100,309 |
Income Statement
The Company’s U.S. GAAP results for the three months ended June 30, 2026 included special items which impacted the U.S. GAAP measures as follows:
| Total revenues | Gross profit | Selling, general and administrative | Research and development | Restructuring, strategic transaction and integration | Income from operations | Interest expense, net | Income before income taxes and equity in income of unconsolidated affiliates | Provision for income taxes | Provision for income taxes | Net income from consolidated companies | Equity in earnings of unconsolidated affiliated | Net income (loss) | Diluted earnings (loss) income per share | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (GAAP) | 551,683 | 235,053 | 151,922 | 22,702 | 21,302 | 39,127 | -15,747 | 23,144 | -7,070 | 16,074 | 3,013 | 19,087 | 0.76 | |
| Reported percent of total revenues or (percent of income (loss) before income taxes and equity in earnings of unconsolidated affiliates) | 43 | 28 | 4 | 4 | 7 | -3 | 4 | 30.5 | 30.5% | 3 | ||||
| Contract manufacturing | -3,799 | -575 | -575 | -575 | 141 | -434 | -434 | -0.02 | ||||||
| Stock compensation expense | 1,850 | -9,249 | -771 | 11,870 | 11,870 | -2,879 | 8,991 | 8,991 | 0.36 | |||||
| Amortization expense | 1,265 | -31,722 | 32,987 | 32,987 | -8,200 | 24,787 | 24,787 | 0.99 | ||||||
| Restructuring, strategic transaction and integration | -21,302 | 21,302 | 21,302 | -5,049 | 16,253 | 16,253 | 0.65 | |||||||
| Settlements | -30 | 30 | 30 | -7 | 23 | 23 | ||||||||
| Quality system and product-related remediation | 5,890 | 5,890 | 5,890 | -1,265 | 4,625 | 4,625 | 0.18 | |||||||
| Noncash release of loss on contract provision | 1,120 | -1,120 | 318 | -802 | 196 | -606 | -606 | -0.02 | ||||||
| Tariff refunds | -18,888 | -18,888 | -710 | -19,598 | 4,802 | -14,796 | -14,796 | -0.59 | ||||||
| Tax benefit from discrete reserve release and valuation allowance* | 1,548 | 1,548 | 1,548 | 0.06 | ||||||||||
| Tax benefit from equity in loss of unconsolidated affiliates | 738 | 738 | -738 | |||||||||||
| Adjusted (Non-GAAP)** | 547,884 | 224,595 | 112,041 | 21,931 | $— | 90,623 | -16,139 | 74,248 | -17,045 | 57,203 | 2,275 | 59,478 | 2.37 | |
| Adjusted percent of total revenues or (percent of (loss) income before income taxes and equity in loss of unconsolidated affiliates for benefit (provision) for income taxes) | 41 | 20 | 4 | 17 | -3 | 14 | 23 | 23.0% | 10 |
Income Statement
(In thousands) (in thousands)
| Net Debt – As of June 30, 2026 | TTM Adjusted EBITDA – As of June 30, 2026 | Net Leverage Ratio | Net Debt – As of June 30, 2026 | TTM Adjusted EBITDA – As of June 30, 2026 | Net Leverage Ratio | ||
|---|---|---|---|---|---|---|---|
| Net Leverage Ratio Calculation | Current portion of long-term debt | 18,750 | |||||
| Net Leverage Ratio Calculation | Long-Term Debt | 1,212,449 | |||||
| Net Leverage Ratio Calculation | Total GAAP Long-Term Debt | 1,231,199 | |||||
| Net Leverage Ratio Calculation | Add: Unamortized Debt Issuance Costs/Discounts(1) | 8,614 | |||||
| Net Leverage Ratio Calculation | Less: Cash and cash equivalents | -298,299 | |||||
| Net Leverage Ratio Calculation | Net Debt (Non-GAAP) | 941,514 | |||||
| (1) Represents unamortized debt issuance costs and original issue discounts deducted from the carrying value of long-term debt on the Condensed Consolidated Balance Sheets in accordance with U.S. GAAP. Management adds back these costs to present total contractual principal obligations outstanding when evaluating debt leverage. | GAAP net income | 30,089 | |||||
| Non-GAAP adjustments: | Interest, net | 72,692 | |||||
| Non-GAAP adjustments: | Stock compensation expense | 55,003 | |||||
| Non-GAAP adjustments: | Depreciation and amortization expense | 201,273 | |||||
| Non-GAAP adjustments: | Restructuring, strategic transaction and integration | 71,693 | |||||
| Non-GAAP adjustments: | Settlements | 1,596 | |||||
| Non-GAAP adjustments: | Quality system and product-related remediation | 38,070 | |||||
| Non-GAAP adjustments: | Asset write-offs and similar charges | 887 | |||||
| Non-GAAP adjustments: | Gain on sale of business | -2,969 | |||||
| Non-GAAP adjustments: | Noncash release of loss on contract provision | -4,392 | |||||
| Non-GAAP adjustments: | Gross profit on contract manufacturing | -1,292 | |||||
| Non-GAAP adjustments: | Tariff refunds | -18,888 | |||||
| Non-GAAP adjustments: | Provision for income taxes | -30,955 | |||||
| Non-GAAP adjustments: | Total non-GAAP adjustments | 382,718 | |||||
| Non-GAAP adjustments: | TTM Adjusted EBITDA | 412,807 | |||||
| Non-GAAP adjustments: | Net Debt | 941,514 | |||||
| Non-GAAP adjustments: | Divided by: TTM Adjusted EBITDA | 412,807 | |||||
| Non-GAAP adjustments: | Net Leverage Ratio | 2.28 |
Income Statement
(In millions, except per share data)
| Low End of Guidance | High End of Guidance | ||
|---|---|---|---|
| GAAP net income | 73 | 83 | |
| Non-GAAP adjustments: | Interest, net | 65 | 65 |
| Non-GAAP adjustments: | Stock compensation expense | 50 | 50 |
| Non-GAAP adjustments: | Depreciation and amortization expense | 203 | 203 |
| Non-GAAP adjustments: | Restructuring, strategic transaction and integration | 52 | 52 |
| Non-GAAP adjustments: | Quality and regulatory initiatives and remediation | 25 | 25 |
| Non-GAAP adjustments: | Noncash release of loss on contract provision | -4 | -4 |
| Non-GAAP adjustments: | Gross profit on contract manufacturing | -2 | -2 |
| Non-GAAP adjustments: | Tariff refunds | -19 | -19 |
| Non-GAAP adjustments: | Benefit for income taxes | -28 | -18 |
| Non-GAAP adjustments: | Total non-GAAP adjustments | 342 | 352 |
| Non-GAAP adjustments: | Adjusted EBITDA | 415 | 435 |
| Non-GAAP adjustments: | GAAP income per share | 2.89 | 3.29 |
| Non-GAAP adjustments: | Stock compensation expense | 1.98 | 1.98 |
| Non-GAAP adjustments: | Amortization expense | 5.28 | 5.28 |
| Non-GAAP adjustments: | Restructuring, strategic transaction and integration | 2.06 | 2.06 |
| Non-GAAP adjustments: | Quality and regulatory initiatives and remediation | 0.99 | 0.99 |
| Non-GAAP adjustments: | Noncash release of loss on contract provision | -0.12 | -0.12 |
| Non-GAAP adjustments: | Gross profit on contract manufacturing | -0.08 | -0.08 |
Balance Sheet
(In thousands) (in thousands)
| June 30, 2026 | December 31, 2025 | ||
|---|---|---|---|
| CURRENT ASSETS: | Cash and cash equivalents | 298,299 | 307,963 |
| CURRENT ASSETS: | Accounts receivable, net of allowance for doubtful accounts | 183,531 | 180,515 |
| CURRENT ASSETS: | Inventories | 607,421 | 615,859 |
| CURRENT ASSETS: | Prepaid expenses and other current assets | 121,657 | 86,217 |
| CURRENT ASSETS: | TOTAL CURRENT ASSETS | 1,210,908 | 1,190,554 |
| CURRENT ASSETS: | PROPERTY, PLANT AND EQUIPMENT, net | 446,798 | 451,817 |
| CURRENT ASSETS: | OPERATING LEASE RIGHT-OF-USE ASSETS | 38,610 | 54,470 |
| CURRENT ASSETS: | GOODWILL | 1,484,384 | 1,499,754 |
| CURRENT ASSETS: | INTANGIBLE ASSETS, net | 567,665 | 633,559 |
| CURRENT ASSETS: | DEFERRED INCOME TAXES | 25,569 | 25,891 |
| CURRENT ASSETS: | OTHER ASSETS | 63,435 | 62,877 |
| CURRENT ASSETS: | INVESTMENTS IN UNCONSOLIDATED AFFILIATES | 133,913 | 131,586 |
| CURRENT ASSETS: | TOTAL ASSETS | 3,971,282 | 4,050,508 |
| CURRENT LIABILITIES: | Accounts payable | 149,165 | 154,374 |
| CURRENT LIABILITIES: | Accrued liabilities | 322,489 | 315,337 |
| CURRENT LIABILITIES: | Current portion of long-term debt | 18,750 | 18,750 |
| CURRENT LIABILITIES: | Income tax payable | 7,960 | 10,400 |
| CURRENT LIABILITIES: | TOTAL CURRENT LIABILITIES | 498,364 | 498,861 |
| CURRENT LIABILITIES: | LONG-TERM DEBT | 1,212,449 | 1,265,917 |
| CURRENT LIABILITIES: | OTHER LONG-TERM LIABILITIES | 70,994 | 89,536 |
| CURRENT LIABILITIES: | DEFERRED INCOME TAXES | 12,227 | 37,756 |
| CURRENT LIABILITIES: | INCOME TAX LIABILITY | 25,397 | 34,613 |
| STOCKHOLDERS’ EQUITY: | Common stock, $0.10 par value; Authorized — 80,000 shares; Issued —25,186 and 24,688 shares at June 30, 2026 and December 31, 2025, respectively, and outstanding — 25,007 and 24,688 shares at June 30, 2026 and December 31, 2025, respectively | 2,519 | 2,469 |
| STOCKHOLDERS’ EQUITY: | Additional paid-in capital | 1,475,974 | 1,465,118 |
| STOCKHOLDERS’ EQUITY: | Treasury stock, at cost | -23,415 | -22 |
| STOCKHOLDERS’ EQUITY: | Retained earnings | 740,109 | 690,890 |
| STOCKHOLDERS’ EQUITY: | Accumulated other comprehensive loss | -43,336 | -34,630 |
| STOCKHOLDERS’ EQUITY: | TOTAL STOCKHOLDERS' EQUITY | 2,151,851 | 2,123,825 |
| STOCKHOLDERS’ EQUITY: | TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | 3,971,282 | 4,050,508 |
Cash Flow
Six months ended June 30, — (In thousands) (in thousands)
| Six months ended June 30, – 2026 | Six months ended June 30, – 2025 | ||
|---|---|---|---|
| CASH FLOWS FROM OPERATING ACTIVITIES: | Net income | 49,219 | 19,862 |
| Adjustments to reconcile net loss to net cash provided by operating activities: | Depreciation and amortization | 99,640 | 99,110 |
| Adjustments to reconcile net loss to net cash provided by operating activities: | Noncash lease expense | 8,136 | 9,308 |
| Adjustments to reconcile net loss to net cash provided by operating activities: | Stock compensation | 25,881 | 26,636 |
| Adjustments to reconcile net loss to net cash provided by operating activities: | Loss on disposal of property, plant and equipment and other assets | 1,983 | 1,753 |
| Adjustments to reconcile net loss to net cash provided by operating activities: | Debt issuance costs amortization | 1,574 | 3,482 |
| Adjustments to reconcile net loss to net cash provided by operating activities: | Undistributed equity in earnings of unconsolidated affiliates | -2,406 | -2,837 |
| Adjustments to reconcile net loss to net cash provided by operating activities: | Gain on sale of business | -41,823 | |
| Adjustments to reconcile net loss to net cash provided by operating activities: | Other | 13,471 | 8,037 |
| Changes in operating assets and liabilities, net of amounts acquired: | Accounts receivable | -7,562 | 16,691 |
| Changes in operating assets and liabilities, net of amounts acquired: | Inventories | 4,625 | -29,213 |
| Changes in operating assets and liabilities, net of amounts acquired: | Prepaid expenses and other current assets | -16,461 | -9,208 |
| Changes in operating assets and liabilities, net of amounts acquired: | Other assets | -2,936 | -5,682 |
| Changes in operating assets and liabilities, net of amounts acquired: | Accounts payable | -4,909 | 14,382 |
| Changes in operating assets and liabilities, net of amounts acquired: | Accrued liabilities | -5,895 | -19,835 |
| Changes in operating assets and liabilities, net of amounts acquired: | Income taxes, including excess tax benefits and deferred income taxes | -45,301 | -28,125 |
| Changes in operating assets and liabilities, net of amounts acquired: | Net cash provided by operating activities | 119,059 | 62,538 |
| CASH FLOWS FROM INVESTING ACTIVITIES: | Purchases of property, plant and equipment | -29,813 | -34,317 |
| CASH FLOWS FROM INVESTING ACTIVITIES: | Proceeds from the sale of business | 209,464 | |
| CASH FLOWS FROM INVESTING ACTIVITIES: | Deposit received for the sale of a business | 2,000 | |
| CASH FLOWS FROM INVESTING ACTIVITIES: | Proceeds from sale of assets | 22 | 42 |
| CASH FLOWS FROM INVESTING ACTIVITIES: | Intangible asset additions | -3,555 | -4,541 |
| CASH FLOWS FROM INVESTING ACTIVITIES: | Net cash (used in) provided by investing activities | -31,346 | 170,648 |
| CASH FLOWS FROM FINANCING ACTIVITIES: | Principal repayments of long-term debt | -54,688 | -247,750 |
| CASH FLOWS FROM FINANCING ACTIVITIES: | Proceeds from exercise of stock options | 490 | 5,972 |
| CASH FLOWS FROM FINANCING ACTIVITIES: | Payments on finance leases | -1,297 | -885 |
| CASH FLOWS FROM FINANCING ACTIVITIES: | Tax withholding payments related to net share settlement of equity awards | -38,862 | -8,688 |
| CASH FLOWS FROM FINANCING ACTIVITIES: | Net cash used in financing activities | -94,357 | -251,351 |
| CASH FLOWS FROM FINANCING ACTIVITIES: | Effect of exchange rate changes on cash | -3,020 | 9,624 |
Cash Flow
(In thousands) (in thousands)
| Reconciliation of Net Cash Provided by Operating Activities to Free Cash Flow – Three months ended June 30, – 2026 | Reconciliation of Net Cash Provided by Operating Activities to Free Cash Flow – Three months ended June 30, – 2025 | Reconciliation of Net Cash Provided by Operating Activities to Free Cash Flow – Six months ended June 30, – 2026 | Reconciliation of Net Cash Provided by Operating Activities to Free Cash Flow – Six months ended June 30, – 2025 | |
|---|---|---|---|---|
| Net cash provided by operating activities | 80,150 | 11,211 | 119,059 | 62,538 |
| Purchase of property, plant and equipment | -18,511 | -19,696 | -29,813 | -34,317 |
| Proceeds from sale of assets | 21 | 22 | 42 | |
| Free cash flow | 61,660 | -8,485 | 89,268 | 28,263 |
Full release
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements contain words such as
“aim,” “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” or the negative thereof or comparable terminology and may include (without limitation) information regarding the Company's expectations, goals and intentions regarding the future and financial outlook for 2026. These forward-looking statements are based on management's current expectations, estimates, forecasts and projections about the Company and assumptions management believes are reasonable, all of which are subject to risks and uncertainties that could cause actual results and events to differ materially from those stated in the forward-looking statements. These risks and uncertainties include, but are not limited to: risks from doing business in foreign countries, including related to tariffs and other barriers to trade; the Company’s ability to compete successfully, including with larger international companies and established local companies; decreased demand for the Company's products; costs related to product development; cost volatility or potential loss of supply of raw materials due to our dependence on single and limited source third-party suppliers; ability to achieve operating efficiencies; risks related to significant sales through our distributors; inflation and foreign currency exchange rates; impacts from global macroeconomic and geopolitical conditions, including from escalated conflicts in the Middle East and associated disruptions to shipping and increased oil costs; healthcare costs and reimbursement levels; disruptions at the FDA and other governmental agencies; damage at the Company’s manufacturing or supply facilities; risks associated with the IV Solutions joint venture and the Smiths Medical integration; risks associated with the timing and resolution of the 2025 warning letter; risks related to protection of our information technology systems and compliance with privacy laws and regulations; risks related to our intellectual property; and the other important factors described under “Risk Factors” in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and our subsequent filings with the SEC. Forward-looking statements contained in this press release are made only as of the date hereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise unless required by law.